SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
+9.29%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$392M
AUM Growth
+$392M
(+21%)
Cap. Flow
+$47M
Cap. Flow
% of AUM
12%
Top 10 Holdings %
Top 10 Hldgs %
39.92%
Holding
132
New
31
Increased
30
Reduced
24
Closed
25
Top Buys
| 1 |
Biogen
BIIB
|
$20.5M |
| 2 |
Novartis
NVS
|
$19M |
| 3 |
Pfizer
PFE
|
$13.3M |
| 4 |
SHPG
Shire pic
SHPG
|
$13.1M |
| 5 |
CELG
Celgene Corp
CELG
|
$8.71M |
Top Sells
| 1 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$13.8M |
| 2 |
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
|
$13M |
| 3 |
Teva Pharmaceuticals
TEVA
|
$11.2M |
| 4 |
Merck
MRK
|
$9.85M |
| 5 |
AKAO
Achaogen, Inc.
AKAO
|
$7.93M |
Sector Composition
| 1 | Healthcare | 77.61% |
| 2 | Technology | 5.72% |
| 3 | Communication Services | 2.6% |
| 4 | Industrials | 2.35% |
| 5 | Consumer Discretionary | 1.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $31.1M | 6.08% | 250,000 +70,000 | +39% | +$8.71M |
|
|
2
Biogen
BIIB
$19.4B
| $20.5M | 4.01% | +75,000 | New | +$20.5M |
|
|
3
Novartis
NVS
$245B
| $19M | 3.71% | +255,000 | New | +$19M |
|
|
4
Merck
MRK
$210B
| $18.7M | 3.66% | 295,000 -155,000 | -34% | -$9.85M |
|
|
SHPG
5
DELISTED
Shire pic
SHPG
| $15.4M | 3.02% | 214,539 +182,039 | +560% | +$13.1M |
|
6
Sarepta Therapeutics
SRPT
$1.78B
| $14.3M | 2.8% | 483,047 +85,000 | +21% | +$2.52M |
|
|
7
Pfizer
PFE
$141B
| $13.3M | 2.61% | +390,000 | New | +$13.3M |
|
8
Ituran Location and Control
ITRN
$671M
| $8.68M | 1.7% | 281,356 -25,277 | -8% | -$780K |
|
9
Bristol-Myers Squibb
BMY
$96B
| $8.16M | 1.59% | +150,000 | New | +$8.16M |
|
10
Ascendis Pharma
ASND
$11.8B
| $7.15M | 1.4% | 255,455 -71,167 | -22% | -$1.99M |
|
|
HZNP
11
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $7.09M | 1.39% | 480,000 +180,000 | +60% | +$2.66M |
|
12
Neurocrine Biosciences
NBIX
$13.8B
| $6.5M | 1.27% | +150,000 | New | +$6.5M |
|
|
ARAV
13
DELISTED
Aravive, Inc. Common Stock
ARAV
| $6.41M | 1.25% | 300,000 +50,000 | +20% | +$1.07M |
|
|
ARRY
14
DELISTED
Array Biopharma Inc
ARRY
| $6.26M | 1.22% | 700,000 -200,000 | -22% | -$1.79M |
|
|
IMMU
15
DELISTED
Immunomedics Inc
IMMU
| $6.15M | 1.2% | 950,000 -100,000 | -10% | -$647K |
|
16
Corvus Pharmaceuticals
CRVS
$428M
| $5.8M | 1.13% | 279,166 -41,063 | -13% | -$853K |
|
|
17
Teva Pharmaceuticals
TEVA
$21.1B
| $5.52M | 1.08% | 172,000 -350,000 | -67% | -$11.2M |
|
|
ORBK
18
DELISTED
Orbotech Ltd
ORBK
| $5.07M | 0.99% | 157,096 +111,875 | +247% | +$3.61M |
|
|
AKAO
19
DELISTED
Achaogen, Inc.
AKAO
| $5.05M | 0.99% | 200,000 -314,342 | -61% | -$7.93M |
|
20
Visa
V
$683B
| $4.71M | 0.92% | 52,951 +1,000 | +2% | +$88.9K |
|
|
EIGR
21
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $4.41M | 0.86% | 385,301 | – | – |
|
22
Ardelyx
ARDX
$1.53B
| $4.36M | 0.85% | 345,000 +193,187 | +127% | +$2.44M |
|
23
Nice
NICE
$8.73B
| $4.32M | 0.84% | 63,520 +25,197 | +66% | +$1.71M |
|
|
CBIO
24
Crescent Biopharma, Inc. Common Stock
CBIO
$200M
| $4.21M | 0.82% | 775,796 +30,000 | +4% | +$163K |
|
25
TherapeuticsMD
TXMD
$12.8M
| $4.18M | 0.82% | +580,000 | New | +$4.18M |
|